
Anixa Biosciences ANIX
$ 2.86
0.7%
Quarterly report 2025-Q4
added 03-09-2026
Anixa Biosciences P/E Ratio 2011-2026 | ANIX
Annual P/E Ratio Anixa Biosciences
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -0.00947 | -0.00564 | -0.0154 | -0.0101 | -4.64 | -5.81 | -6.51 | -4.94 | -6.09 | -10.9 | -19.6 | -4.23 | -4.5 | -9.39 | -3.23 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -0.00564 | -19.6 | -5.33 |
P/E Ratio of other stocks in the Diagnostics research industry
| Issuer | P/E Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Centogene N.V.
CNTG
|
-10.3 | - | -6.23 % | $ 30.6 M | ||
|
Akumin
AKU
|
-0.479 | - | -17.87 % | $ 25.9 M | ||
|
Brainsway Ltd.
BWAY
|
-37.1 | $ 14.0 | 2.56 % | $ 99.4 M | ||
|
Aspira Women's Health
AWH
|
-1.67 | - | -6.19 % | $ 10.5 M | ||
|
Bioventus
BVS
|
26.7 | $ 8.91 | 0.51 % | $ 594 M | ||
|
Castle Biosciences
CSTL
|
38.9 | $ 25.85 | 0.08 % | $ 718 M | ||
|
Oxford Immunotec Global PLC
OXFD
|
-233 | - | - | $ 562 M | ||
|
DexCom
DXCM
|
30.5 | $ 67.92 | 2.38 % | $ 26.5 B | ||
|
Charles River Laboratories International
CRL
|
-53.3 | $ 157.08 | 3.45 % | $ 7.79 B | ||
|
CareDx, Inc
CDNA
|
-46.5 | $ 17.51 | 1.07 % | $ 933 M | ||
|
Accelerate Diagnostics
AXDX
|
-2.76 | - | -61.36 % | $ 2.46 M | ||
|
Exact Sciences Corporation
EXAS
|
-93.8 | $ 103.81 | -0.04 % | $ 19.6 B | ||
|
Guardant Health
GH
|
-32.3 | $ 87.36 | 0.2 % | $ 11 B | ||
|
Global Cord Blood Corporation
CO
|
0.485 | - | - | $ 399 M | ||
|
Fluidigm Corporation
FLDM
|
-9.08 | - | 1.08 % | $ 308 M | ||
|
Genetic Technologies Limited
GENE
|
-1.29 K | - | - | $ 7.1 B | ||
|
Genetron Holdings Limited
GTH
|
-3.07 | - | 0.12 % | $ 80.1 M | ||
|
Fulgent Genetics
FLGT
|
-10.9 | $ 15.45 | 3.34 % | $ 467 M | ||
|
PRA Health Sciences, Inc.
PRAH
|
39.9 | - | - | $ 10.7 B | ||
|
Biodesix
BDSX
|
-2.14 | $ 17.14 | -0.87 % | $ 2.22 B | ||
|
ICON Public Limited Company
ICLR
|
21 | $ 100.87 | 3.33 % | $ 8.32 B | ||
|
IQVIA Holdings
IQV
|
20.8 | $ 170.64 | 3.54 % | $ 29.3 B | ||
|
Danaher Corporation
DHR
|
41.4 | $ 196.09 | 2.46 % | $ 140 B | ||
|
Biocept
BIOC
|
-0.185 | - | -13.05 % | $ 7.29 M | ||
|
Heska Corporation
HSKA
|
-42.4 | - | - | $ 1.31 B | ||
|
HTG Molecular Diagnostics
HTGM
|
-0.138 | - | -20.0 % | $ 1.06 M | ||
|
Illumina
ILMN
|
-13.4 | $ 120.51 | 1.03 % | $ 19.2 B | ||
|
Quest Diagnostics Incorporated
DGX
|
23.5 | $ 199.89 | 0.48 % | $ 22.2 B | ||
|
QIAGEN N.V.
QGEN
|
102 | - | - | $ 10.6 B | ||
|
Agilent Technologies
A
|
34.7 | $ 114.44 | 2.33 % | $ 34.8 B | ||
|
BioNano Genomics
BNGO
|
-0.0317 | $ 1.11 | -0.45 % | $ 1.41 M | ||
|
DarioHealth Corp.
DRIO
|
-0.73 | $ 8.74 | 3.8 % | $ 248 M | ||
|
Neogen Corporation
NEOG
|
-0.933 | $ 9.31 | 2.2 % | $ 2.02 B | ||
|
Lantheus Holdings
LNTH
|
21.9 | $ 78.85 | 0.45 % | $ 5.32 B | ||
|
Chembio Diagnostics
CEMI
|
-0.54 | - | 0.22 % | $ 16.8 M | ||
|
Check-Cap Ltd.
CHEK
|
-0.172 | - | - | $ 9.42 M | ||
|
Pacific Biosciences of California
PACB
|
-0.911 | $ 1.39 | 1.84 % | $ 417 M | ||
|
Co-Diagnostics
CODX
|
-0.988 | $ 4.4 | 101.83 % | $ 129 M | ||
|
Medpace Holdings
MEDP
|
28.7 | $ 461.07 | 1.64 % | $ 13.3 B | ||
|
Motus GI Holdings
MOTS
|
-0.0769 | - | -34.28 % | $ 263 K | ||
|
Mettler-Toledo International
MTD
|
32.7 | $ 1 224.83 | 2.14 % | $ 25.2 B | ||
|
Celcuity
CELC
|
-3.57 | $ 113.19 | -1.49 % | $ 4.47 B | ||
|
DermTech
DMTK
|
-0.421 | - | -11.32 % | $ 2.94 M | ||
|
National Research Corporation
NRC
|
27.2 | $ 18.02 | 3.56 % | $ 403 M | ||
|
NeoGenomics
NEO
|
-13.7 | $ 8.4 | 2.0 % | $ 1.08 B | ||
|
Invitae Corporation
NVTA
|
-5.12 | - | - | $ 21.2 M | ||
|
Enzo Biochem
ENZ
|
-0.00221 | - | -8.98 % | $ 14.8 K | ||
|
Natera
NTRA
|
-9.69 | $ 201.85 | 2.11 % | $ 19.9 B | ||
|
OPKO Health
OPK
|
86.6 | $ 1.2 | 0.84 % | $ 833 M |